Biotech firm Illumina, Inc. (NASDAQ: ILMN) scrapped a merger with Pacific Biosciences, but there’s still a lot to like about Illumina and for investors that can’t handle the stock’s over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG) is an adequate...